Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00616915
Other study ID # PSIY-219-05
Secondary ID
Status Completed
Phase Phase 1
First received February 4, 2008
Last updated December 14, 2015
Start date January 2007
Est. completion date January 2010

Study information

Verified date December 2015
Source Queen's University
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

Wellbutrin (bupropion) is an effective antidepressant (Thase, M 2005). It exists in instant release (IR), sustained release (SR) and extended release (XL) forms. The IR formulation was never approved for use in Canada. The XL formulation allows for once daily dosing.

Wellbutrin is both a norepinephrine and dopamine reuptake inhibitor, and as such increases the synaptic concentration of both neurotransmitters. This adds to its positive effects on cognition, apathy, tiredness and executive functioning. The increased activation may be also responsible for some of its side effects such as initial insomnia and reduced sleep efficiency, especially when taken at night.


Description:

Wellbutrin SR formulation cannot be given as more than 150 mg as a single dose and higher doses are commonly required for the treatment of depression; they also have to be given at least 8 hours apart in order to avoid peak plasma concentrations and to reduce the risk of seizures (incidence of 0.1% at doses £ 300 mg). The twice a day dosing may result in complaints of insomnia and may necessitate discontinuing the medication or adding a sleep promoting agent. The benefit of once-daily dosing cannot be understated given treatment adherence is typically lower in depressed patients than their non-depressed counterparts; further, the 8 h dosing interval of bupropion SR is likely to have lower adherence compared with traditional bid dosing (i.e., morning and evening); thus, it is not difficult to imagine patients missing 30-50% of their second dose given the difficulty of recalling to take the second dose at work or school. The review of Fava et al. (2005) plots the relative PK profiles of XL and SR and notes the significantly lower bupropion concentration at bedtime, which is likely to reduce the occurrence of insomnia. Therefore, Wellbutrin XL may improve adherence by eliminating the second dose and Wellbutrin XL also avoids the high plasma drug concentrations at bedtime, as seen with bupropion SR, which are associated with insomnia. Further, the smoother pharmacokinetic profile of Wellbutrin XL may improve overall tolerability compared with Wellbutrin SR.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date January 2010
Est. primary completion date January 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Signed Patient Informed Consent;

2. Patients with Major Depressive Disorders (DSM-IV-TR - criteria used);

3. Out-patients;

4. Males or females over 18 years of age;

5. Patients currently using Wellbutrin SR.

Exclusion Criteria:

1. Bipolar Disorder patients;

2. Actively suicidal patients;

3. Schizophrenia, Schizoaffective or other Psychotic Disorder;

4. Pregnant women, as by pregnancy test at the beginning of the study;

5. Women in childbearing age, refusing to use appropriate contraception, or breastfeeding mothers;

6. Patients with known hypersensitivity to bupropion;

7. Patients with severe or unstable medical conditions, which in the opinion of the investigator would interfere with their progress or safety;

8. ECT or TMS treatments within the last three months;

9. Patients who did not respond to previous treatment with bupropion;

10. Patients with history of seizure disorder;

11. Patients with history of eating disorders (e.g. bulimia, anorexia nervosa);

12. Patients using sleep aiding medication (Benzodiazepines, barbiturates).

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Wellbutrin XL
Wellbutrin XL 300mg daily

Locations

Country Name City State
Canada Providence Care Mental Health Services Kingston Ontario

Sponsors (1)

Lead Sponsor Collaborator
Queen's University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary This study is looking at the effect of Wellbutrin SR versus Wellbutrin XL on sleep quality pre, 3-5days, 3-4weeks after wellbutrinXL No
See also
  Status Clinical Trial Phase
Completed NCT00001919 - Neuroimaging of St. John's Wort-Induced Changes of Serotonin Metabolism in Normal Subjects N/A
Completed NCT00026832 - Examination of Brain Serotonin Receptors in Patients With Mood Disorders
Completed NCT01951508 - Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study Phase 0
Terminated NCT01830088 - Family Based Treatment of Depressed Adolescents (AHUS) N/A
Completed NCT01269710 - Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study N/A
Completed NCT00001146 - Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial Phase 2
Completed NCT00001170 - Study of the Psychological Development of Children of Parents With and Without Affective Disorders N/A
Completed NCT00001192 - Neuropsychological Evaluation of Psychiatric and Neurological Patients N/A
Completed NCT02189057 - A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression N/A
Completed NCT01473550 - Mental Health Engagement Network (MHEN) N/A
Completed NCT00990067 - Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Phase 1
Completed NCT00794040 - A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation Phase 2
Completed NCT02819986 - Effectiveness of Using the Progressive Goal Attainment Program in Anxiety and Mood Disorders N/A
Completed NCT03538860 - Validation of an Automated Online Language Interpreting Tool - Phase Two. N/A
Completed NCT00016731 - Adolescence, Puberty, and Emotion Regulation
Completed NCT02721316 - Outpatient Nurse Monitoring Under the Prevention of Recurrent Suicidal N/A
Recruiting NCT02443636 - The Canadian Depression Research and Intervention Network (CDRIN) Maritimes Registry
Terminated NCT01493323 - Functional Imaging of Psychic Pain N/A
Completed NCT00699218 - A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression N/A
Completed NCT00001654 - The Role of Emotion in the Development of Psychopathology N/A